![\"News](\"https:\/\/media.healthday.com\/Images\/icimages\/girl_hospital_bed64.jpg\"\/)
<\/p>\n
FRIDAY, Sept. 25, 2020 (HealthDay News)<\/p>\n
Kids and adults have different immune system responses to infection with the new coronavirus, which may help explain why severe COVID-19<\/a> is more common in adults, researchers report.<\/p>\n For their new study, they examined blood and cell samples from patients admitted with COVID-19<\/a> symptoms to the Montefiore Medical Center in New York City.<\/p>\n The researchers found that the younger the patient, the higher their levels of two immune system molecules, interleukin 17A (IL-17A) and interferon<\/a> gamma (INF-g).<\/p>\n IL-17A helps trigger immune system response during early infection and INF-g combats replication of the virus. Higher levels of the two molecules may be associated with better outcomes in COVID-19<\/a> patients, according to the authors.<\/p>\n “To our surprise, we found these particular serum cytokines were at higher levels in children than adults,” co-senior study author Dr. Kevan Herold, a professor of immunology and internal medicine at Yale University, said in a Yale news release.<\/p>\n Researchers were also surprised to find that certain antibody responses thought to be protective were higher in adults, including those with severe COVID-19<\/a>, than in children.<\/p>\n IL-17A and INF-g are part of the innate immune system, a more primitive, non-specific response activated early after infection. On the other hand, adults had a more vigorous adaptive immune system response, including higher levels of antibodies that attack the new coronavirus.<\/p>\n The findings suggest “that kids have a more robust, earlier innate immune response to the virus, which may protect them from progressing to severe pulmonary disease,” said co-senior study author Dr. Betsy Herold, a professor of pediatrics<\/a> and microbiology-immunology at Albert Einstein College of Medicine in New York City.<\/p>\n The study included children and teens<\/a> with multi-system inflammatory syndrome (MIS-C), a rare complication of COVID-19<\/a> infection in young people that’s associated with a range of severe health complications.<\/p>\n Like other youngsters, those with MIS-C also have high levels of IL-17A and INF-g, and rarely develop the severe lung damage seen in adults with severe COVID-19<\/a>.<\/p>\n The findings suggest that boosting certain types of immune responses may benefit COVID-19 patients, the researchers said.<\/p>\n The study was published recently in the journal Science Translational Medicine<\/i>.<\/p>\n — Robert Preidt<\/p>\n ![\"MedicalNews\"](\"https:\/\/images.medicinenet.com\/images\/HealthDay\/healthday.png\")
Copyright \u00a9 2020 HealthDay. All rights reserved.<\/p>\n
\n
\n ![](\"https:\/\/images.medicinenet.com\/\/images\/slideshow\/childhood-illnesses-s1-sick-child-wiping-nose.jpg\"\/)
\n